alnylam
The Director, Epidemiology provides strategic vision and oversight for epidemiology and real-world evidence activities at Alnylam, supporting clinical development programs and marketed RNAi therapeutics. This role involves analyzing disease incidence and prevalence, guiding clinical study design, and partnering with cross-functional teams to interpret safety signals and develop real-world data strategies. The position requires expertise in epidemiologic methods, regulatory knowledge, and leadership in mentoring junior analysts.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
Associate Director, Epidemiology
GSK plc
Associate Director, Epidemiology (Global Health)
GSK plc
Senior Director, Epidemiology, Europe
Revolution Medicines
Senior Director, Epidemiology, Immunology
Celldex Therapeutics
Senior Director, Respiratory Innovation, VID Global Epidemiology & RWE
GSK plc
Director, Epidemiology
AbbVie